Clinical Trials for Small Cell Lung Cancer

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma, NSCLC, or pancreatic ductal adenocarcinoma are enrolled in cohorts defined by CEACAM5 expression and, for NSCLC, EGFR status. All receive intravenous M9140 (precemtabart tocentecan), an investigational CEACAM5-targeting antibody–drug conjugate that delivers the topoisomerase I inhibitor exatecan.

ClinicalTrials.gov ID: NCT06710132

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic hepatocellular carcinoma, AFP-producing gastric cancer, selected germ cell tumors, or GPC3-positive squamous NSCLC receive intravenous BGB-B2033 alone or with tislelizumab. BGB-B2033 is a bispecific antibody targeting GPC3 and the T-cell costimulatory receptor 4-1BB; patients must have ECOG 0–1 and no prior GPC3- or 4-1BB-directed therapy.

ClinicalTrials.gov ID: NCT06427941

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, recurrent unresectable or advanced mesothelin-positive solid tumors may be eligible if they are heterozygous for HLA-A*02, their tumor has lost HLA-A*02 expression, and they have cells stored through BASECAMP-1. After lymphodepletion, patients receive a single infusion of autologous A2B694 CAR T cells, which use mesothelin activation and HLA-A*02 inhibition to target tumor cells that have lost HLA-A*02.

ClinicalTrials.gov ID: NCT06051695

A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors (ECOG 0–1) and injectable lesions receive intratumoral tolododekin alfa (ANK-101), an alum-binding interleukin-12 therapy designed to retain IL-12 in the tumor and stimulate local immune responses. Expansion cohorts include patients with stage III–IV non-small cell lung cancer with injectable visceral lesions and patients with unresectable high-risk locally advanced or metastatic cutaneous squamous cell carcinoma, who receive ANK-101 plus the PD-1 inhibitor cemiplimab.

ClinicalTrials.gov ID: NCT06171750

Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab With or Without Chemotherapy in Black Patients With NSCLC

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: This study enrolls Black/African American adults with advanced or metastatic NSCLC (EGFR/ALK/ROS1 wild-type), who are treatment-naïve in this setting, to receive standard-of-care pembrolizumab (an anti–PD-1 checkpoint inhibitor) alone or with chemotherapy. All interventions are FDA-approved, and cohort assignment is based on biomarkers such as PD-L1 and ctDNA levels.

ClinicalTrials.gov ID: NCT06745882

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Budigalimab in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic nonsquamous NSCLC are eligible; the randomized portion requires no prior systemic treatment for advanced disease and no known actionable genomic alterations, while dose escalation permits one prior regimen. Treatment combines telisotuzumab adizutecan, an investigational c-Met–targeted antibody–drug conjugate carrying a topoisomerase I inhibitor, with the investigational PD-1 antibody budigalimab; randomized comparators are budigalimab or pembrolizumab plus platinum/pemetrexed.

ClinicalTrials.gov ID: NCT06772623

A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable advanced or metastatic ER-positive/HER2-negative breast cancer, metastatic castration-resistant prostate cancer, or non-small cell lung cancer can enter dose escalation; expansion is limited to breast cancer and prostate cancer. All participants receive oral OP-3136, a KAT6A/KAT6B histone acetyltransferase inhibitor with additional KAT7 activity, without a control arm.

ClinicalTrials.gov ID: NCT06784193

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic NSCLC harboring homozygous MTAP deletion receive AMG 193, a brain-penetrant, MTA-cooperative PRMT5 inhibitor, with treatment selected by histology and molecular features. Combinations include platinum-based chemotherapy plus pembrolizumab, pembrolizumab alone, or sotorasib for KRAS G12C-mutant disease; patients with measurable brain metastases receive AMG 193 alone.

ClinicalTrials.gov ID: NCT06333951

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed or refractory, unresectable locally advanced or metastatic solid tumors, including metastatic castration-resistant prostate cancer, receive MGC026 intravenously every 21 days in dose-escalation or expansion cohorts. MGC026 is a B7-H3–targeting antibody–drug conjugate carrying an exatecan-based topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT06242470

Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination with Low Dose Radiotherapy in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer or Solid Tumors with Bone Metastases

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and locally advanced or metastatic NSCLC, or another advanced solid tumor with bone metastases, may be eligible after progression on or inability to receive standard therapies if all disease sites are amenable to low-dose radiotherapy. Treatment combines low-dose radiotherapy with intravenous KB-GDT-01, a donor-derived gamma-delta T-cell product that may recognize tumor-associated signals without conventional HLA matching.

ClinicalTrials.gov ID: NCT06069570